lupkynis
lupkynis: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | Phase 4 |
FDA Decisions
Frequently asked questions
Who is developing lupkynis?
lupkynis is being developed by Aurinia Pharmaceuticals Inc..
What is lupkynis's latest FDA decision?
The most recent tracked FDA decision for lupkynis is Approval for 1 INDICATIONS AND USAGE LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive th, dated January 22, 2021.
Get deeper analysis on lupkynis
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis